Subtyping of epithelial cells of normal and metaplastic human uterine cervix, using polypeptide-specific cytokeratin antibodies

Differentiation-independent Constitutive Expression of the Human Papillomavirus Type 16 E6 and E7 Oncogenes in the CaSki Cervical Tumour Cell Line

“…2 and 3). K13 is a marker of cervical cell differentiation both in vivo (Czernobilsky et al, 1984;Levy et al, 1988) and in vitro (Agarwal et al, 1991;Choo et al, 1993;Gorodeski et al, 1990a;Sizemore et aI., 1993) and is specifically expressed in the suprabasal layers of the cervix. In ECE16-1 cells, K13 levels increase when cells are shifted from low to high calcium-containing medium (Choo et al, 1993).…”

“…They serve as useful markers for diagnosing the differentiation status of ectocervical cells (Agarwal et al, 1991;Choo et aL, 1993;Czernobilsky et al, 1984;Dixon & Stanley, 1984;Gorodeski et aL, 1990a;Levy et al, 1988;Moll et al, 1983;Smedts et al, 1990;Weikel et al, 1987). To analyse for cytokeratins, CaSki cells were incubated for 20 h in [3SS]methioninecontaining medium supplemented with the appropriate concentration of calcium chloride exactly as previously described (Choo et al, 1993).…”

Cytoskeleton in neuroectodermally derived epithelial and muscle cells of the human iris and ciliary body.

“…Primary murine monoclonal antibodies (MAb) against cytokeratin 4 (Clone 215 B8, IgGi; Lot 12269420-01; Boehringer Mannheim, Mannheim, Germany) (diluted 1:35), an epitope common to cytokeratins 5 and 6 (Clone D5/16 B4, IgG1; Lot 12269820-01; Boehringer Mannheim) (diluted 1:35), cytokeratin 7 (Clone LdS68, IgGl; Lot 69F4800; Sigma, St Louis, MO) (diluted 1:32000) (21), cytokeratin 13 (Clone KS-lA3, IgGl; Lot 78F-4806; Sigma) (diluted 1:500) (22), three MAb to different epitopes on cytokeratin 18 (Clone CK5, IgG1; Lot 37F-4958; diluted 1:400; Clone CY-90, IgGl; Lot 49F-4815; diluted 1:3000; and Clone KS-B17.2, IgGi, Lot 128F-4805; diluted 1:500) (all from Sigma) (7,22,23), cytokeratin 19 (Clone BA17, IgG1; Lot 109; Dakopatts, Glostrup, Denmark) (diluted 1:lOO) (24), a monoclonal antibody against an epitope common to cytokeratins 8 and 18 (Clone CAM 5.2, IgGza; Lot M0910; Becton Dickinson, Mountain View, CA) (diluted 1:2) (25), and an MAb to a conformational epitope common to most cytokeratin polypeptides, including 8, 18, and 19 (Clone lu-5, IgGl; Lot 10968525-01; Boehringer Mannheim) (diluted 1:lO) (26) were commercially obtained. Murine MAb to vimentin (Clone V9, IgGl; Lot 48F4827) (diluted 1:750) (27,28), desmin (Clone DE-U-10, IgGi; Lot 117F 4809) (diluted 1:400) (29), and a-smooth muscle actin (Clone 1A4, IgG2,; Lot 98F-4808) (diluted 1:SOOO) (30) were also purchased from Sigma, and another mouse MAb to vimentin (Clone Vim 3B4, IgG2,; Lot 11454322-01) (diluted 1:20) was obtained from Boehringer Mannheim.…”

Increased Expression of Cytokeratins 14, 18 and 19 Correlates with Tumor Progression in the Uterine Cervix

“…In low grade SILs, only the upper spinal cells showed immunoreactivi ty while the expression was limited to the differentiated areas in high grade SILs [24]. Acquisition of the squamous epithelial keratins, particularly keratin 13, has been seen in squamous metaplasia of the uterine cervix [12,25], In WDSCCs CK 13 showed intense, focal or patchy grade 4 immunoreactivity with positive tumor cells being fre quently interspaced with CK 13-negative cells. CK 13-deficient areas were quite extensive in some instances, prabably reflecting the loss of a suprabasal epithelial phe notype and the acquisition of the basal cell phenotype.…”